Novartis Kisqali^® Receives European Commission Approval in a Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Novartis announced that the European Commission has approved Kisqali® in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence